BeOne Medicines (HKEX: 06160) has reported positive topline results from the Phase III MANGROVE trial, showing that Brukinsa (zanubrutinib) plus rituximab significantly outperformed standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results